WisdomTree U.S. Multifactor Fund (USMF)
Live price chart, market sentiment, and community perspectives for WisdomTree U.S. Multifactor Fund (CBOE: USMF).
Live price chart, market sentiment, and community perspectives for WisdomTree U.S. Multifactor Fund (CBOE: USMF).
On our risk desk, we are closely tracking USMF's Morningstar risk score of 74, which lands it right in the aggressive bracket despite its low beta of 0.68. With $356.69M in AUM and a standard deviation of 11.26, the fund's defensive posture is clear, but we need to see how the June 2026 index methodology changes affect its tracking error.
When evaluating USMF for core portfolio integration, our quantitative protocol focuses on its multi-factor composite score construction. By filtering for value, quality, momentum, and correlation, the model attempts to capture alpha while dampening correlation shocks. The 0.28% expense ratio keeps the hurdle low for long-term holders.
From a market sentiment perspective, the 3-month sentiment sitting at 66.7% positive reflects steady institutional interest in smart beta blend funds. However, the 1-year fund outflows of $26.53M suggest that allocators are rotating capital elsewhere while waiting to evaluate the impact of the May/June 2026 statutory prospectus supplements.
Looking at the options and volatility characteristics, USMF's R-squared of 61.76 against its index shows a distinct divergence from pure passive tracking. Its Sharpe ratio of 0.62 underperforms the category benchmark's 0.75, signaling that investors are paying a diversification tax in exchange for lower standard deviation.
The broader macroeconomic chatter touches on governance trends, like dual-class share structures in recent IPOs such as SpaceX. While USMF holds a broad all-cap blend of U.S. equities, macro shifts in governance and regulatory scrutiny could indirectly influence the fundamental and quality metrics prioritized by the WisdomTree Core Equity Index Committee.
In our quantitative research group, we noted the upcoming June 11, 2026 effective date for the index provider's methodology changes. Analysts must update their backtests to account for the revised rules-based strategy overseen by WisdomTree Asset Management to ensure no unexpected factor drift occurs.
Explore plasma cleansing, somatic organ swaps, and BCI.